Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04309617 · ClinicalTrials.gov registry record
Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
A clinical trial of Renal Cell Carcinoma, sponsored by Pfizer.
- Completed
- Registry status
- 618
- Enrollment target
- 1
- Study location
NCT04309617 is a study of Renal Cell Carcinoma that has completed, run by Pfizer. The registered enrollment target is 618 participants, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (160% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04309617, a study of Renal Cell Carcinoma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 618 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims at estimating the proportion of patients diagnosed with locoregional renal cell carcinoma who are at high risk for recurrence following nephrectomy, describe referral patterns, and characterize treatment in this population. Outcomes including estimation of the incidence of recurrence and disease-free interval following nephrectomy will be reported overall and among the subgroup off patients receiving adjuvant systemic therapy with sunitinib following nephrectomy.
Conditions Studied
Interventions
- PROCEDURE nephrectomy
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 618 participants |
| Start Date | 2019-07-31 |
| Est. Completion | 2020-04-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04309617
The ClinicalTrials.gov registry entry for NCT04309617 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 618 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (160% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which nephrectomy is the first listed.
NCT04309617 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04309617 about?
NCT04309617 is a clinical study titled "Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy". This study aims at estimating the proportion of patients diagnosed with locoregional renal cell carcinoma who are at high risk for recurrence following nephrectomy, describe referral patterns, and characterize treatment in this population. Outcomes including estimation of the incidence of recurrence...
What is the current status of trial NCT04309617?
This trial is currently completed. The enrollment target is 618 participants. The study started on 2019-07-31. Estimated completion is 2020-04-28.
What conditions does trial NCT04309617 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT04309617?
The interventions under investigation include: nephrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT04309617?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04309617 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.